From blockbuster obesity treatments to expanding diabetes indications, GLP-1 therapies are driving new demands for pharmaceutical packaging and commercialization. As demand accelerates and new market entrants emerge, the focus is shifting beyond drug development to the packaging infrastructure needed to efficiently bring these therapies to market.

While many GLP-1 therapies are manufactured and supplied in primary formats such as pre-filled syringes or injector pens, pharmaceutical companies increasingly rely on specialized contract packaging partners to transform these products into compliant, market-ready configurations through secondary packaging, kitting and labelling services.

The packaging challenges emerging in the GLP-1 market also reflect broader trends across…